SBIR/STTR Research Award
Development of AS01b Mimics by Replacing QS-21 with a New Saponin Adjuvant
Award amount
$600,000Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Adjuvax LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EGVNJG3GMEL7
- Solicitation number
- PHS-2022-1
- Topic code
- 106
Research abstract
AS01b (composed of the molecules QS-21 and MPL) is a powerful adjuvant best known for being a component of the FDA-approved Shingrix vaccine. Despite its successful track-record as an effective adjuvant, accessibility to AS01b as an adjuvant for use in novel vaccines is a concern due to the limited nature of the saponin molecule QS-21. The awardee seeks to address this problem by developing a mimic of AS01b by replacing QS-21 with a novel saponin molecule.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR BASE YEAR - TOPIC 130 ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES
- OPTIMIZE FORMULATION OF VSA ADJUVANT
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Clinical Validation of Myoelectric Implant for Intuitive Prosthesis Control
- Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
- Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
- Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome
- Engineered microglia for the treatment of Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Research funding history
3 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $4,200,000. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services